Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201207127 Principal Investigator: Waqar, Saiama
Title: A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV Non Small Cell Lung Cancer
Phase: II/III Disease Site: Lung
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is to learn if the combination of TG4010 (an agent designed to stimulate your own immune system) and standard treatment is more effective than standard treatment alone (for this, the standard treatment will be given in combination with placebo, which is an inactive product that looks the same as TG4010). Also what are the effects of TG4010 (good and bad) when given with standard treatment.
 
More Information:
ClinicalTrial.gov
Internal Protocol Documents (requires Siteman administrative database password)